- 4009 Hackney Springs Ln, Sachse, TX 75048
UnitedHealthcare is tightening its grip on toxicology labs in Florida, and Modifier 91 has become a major red flag. The rule itself isn’t new; it’s meant for legitimate same-day repeat testing when a subsequent result is clinically necessary. But too many labs have been using it as a blanket workaround for frequency edits, and UHC’s 2026 pre-payment edits are catching it fast.
Florida labs are especially vulnerable. The state’s toxicology market has a history of enforcement actions, including multi-million-dollar settlements, so payers are watching every claim more closely. The real problem isn’t just the modifier; it’s the documentation. If your claim doesn’t clearly spell out why a repeat test was medically necessary that same day, you’re exposed.
The smart move is to audit your own Modifier 91 usage before a payer does. Pull your claims, check your documentation gaps, and make sure your coding and clinical teams are on the same page. As in 2026, using sloppy modifiers is not just a denial risk; it’s an audit risk too.
Just suppose your lab runs multiple same-day drug screens on a patient, appends Modifier 91 out of habit, and moves on. Six months later, a recoupment letter lands on your desk, demanding six figures back. It happens a lot with lab owners.
Toxicology labs in Florida are currently targeted by UnitedHealthcare’s tightened 2026 laboratory enforcement policy. And the trigger, more often than not, traces back to one small piece of code: Modifier 91.
Let’s break down what’s driving this, where labs go wrong, and how you can protect your revenue cycle clean with dedicated laboratory billing services in Florida before an auditor ever comes knocking.
UHC’s claims systems have gotten a lot smarter, and they’re now flagging billing patterns that used to slip through unnoticed. Florida, with its dense concentration of independent and reference toxicology labs, has become one of the most heavily scrutinized markets in the country.
UHC’s own commercial reimbursement policy makes it clear. Modifiers 59, XE, XP, XS, XU, or 91 are required any time a repeat or distinct laboratory service is billed by the same group physician or provider on the same day, and duplicate services without one of those modifiers simply won’t get paid. That sounds simple enough on paper. In practice, it’s where a lot of toxicology billing teams trip up.
Florida has a long, well-documented history of toxicology billing enforcement actions. In one of the largest cases on record, UnitedHealthcare filed suit against five Florida and Texas toxicology labs, alleging a kickback scheme tied to unnecessary drug testing referrals. That case settled for a staggering $56.2 million after UHC’s fraud unit flagged one of the labs as a statistical outlier compared to its peers.
Separately, a Florida-based toxicology lab agreed to pay $4.425 million to resolve federal allegations tied to unnecessary specimen validity and hormone testing billed to Medicare. Neither of those cases was purely a Modifier 91 issue, but they show exactly why payers now watch Florida toxicology claims so closely. Once a market gets this kind of attention, every claim gets a harder look, including the modifier logic.
Modifier 91 tells a payer that you repeated the same lab test on the same patient, on the same day, because you needed a subsequent result to guide treatment. That’s it. It’s not a workaround for a busy day. It’s not a way to dodge a frequency edit.
According to CMS guidance, Modifier 91 is appropriate to indicate that a test is performed multiple times a day for the same patient, only when it’s important to obtain multiple results in the course of treatment.
The Medicare Claims Processing Manual, Chapter 16, Section 100.5.1, spells this out at the federal level, and Novitas Solutions, Florida’s Medicare Administrative Contractor, echoes the same standard in its own Modifier 91 fact sheet.
The Medicare Claims Processing Manual, Chapter 23, is clear that this modifier shouldn’t be used for reporting repeat laboratory testing due to laboratory errors, quality control failures, or anything similar. That means:
None of those situations count as medically necessary subsequent results. If your documentation doesn’t clearly explain why a second (or third) test was clinically required that same day, your lab is prone to an audit trail.
Here’s a scenario that mirrors patterns RCM consultants and lab compliance officers see across the industry, not a specific published audit, but a composite of the situation that plays out again and again.
A mid-size toxicology lab starts appending Modifier 91 to nearly every multi-specimen drug screen claim, treating it as a blanket fix for same-day testing rather than a case-by-case justification. UHC’s frequency-monitoring algorithm eventually flags the pattern as anomalous. An audit follows. The lab can’t produce individualized clinical notes explaining why each repeat test was medically necessary that same day, and the payer initiates recoupment. Depending on claim volume, such exposure can easily run into six figures.
The $56.2 million UHC settlement and the $4.425 million Florida Medicare settlement mentioned earlier both stemmed from the same root problem: billing patterns that didn’t match the clinical documentation behind them. Modifier 91 misuse is simply a smaller, more common version of the same risk.
| Feature | Modifier 91 | Modifier 59 |
|---|---|---|
| What it means | Same test, repeated for a subsequent result | A distinct, separate procedural service |
| Correct use case | Same test, same day, medically necessary follow-up value | Different test, specimen, or site on the same day |
| Most common error | Used to "confirm" or re-run a result | Used when a more specific X-modifier (XE, XP, XS, XU) should apply instead |
| Payer expectation | Documented medical necessity for the repeat | Clear proof the service was truly distinct |
The biggest shift for 2026 isn’t the rule itself. It’s the enforcement model. UHC has been rolling out expanded pre-payment claim editing across its commercial and community plan lines, meaning more claims get scrutinized for diagnosis-to-test alignment and frequency compliance before the check ever gets cut, not months later during a post-payment review.
That’s a meaningful shift for toxicology labs specifically. Under the old “pay and chase” model, a bad billing habit could run for months before anyone noticed. Under a pre-payment edit model, sloppy Modifier 91 use gets caught faster, and denials pile up faster too. Cash flow disruption becomes the more immediate risk, right alongside the audit exposure.
RCM teams can’t fix a documentation gap that starts at the point of care. If the ordering physician’s notes just say “repeat test” without explaining the clinical reasoning, that claim is vulnerable no matter how clean your coding is.
Solid documentation for a Modifier 91 claim should include:
UHC’s own policy Q&A confirms this directly: a separate specimen collection with an appropriate order is required for proper Modifier 91 use, and a vague instruction like “run labs” doesn’t meet the bar for documented intent.
None of this is something you want to get into. But it’s far better than a recoupment letter from the payer.
To make the most out of it, partner with a toxicology lab billing services specialist like TransLabs, which masters Modifier 91 compliance for United Healthcare and all payers across the Sunshine State, assisting you with proper documentation for your claims and providing complete coding support to submit clean claims that get reimbursed fast and keep your practice legally secure for audit risks.
Modifier 91 isn’t a complicated rule. It’s a narrow one, and that’s exactly why it’s so easy to misuse without realizing it. As UHC leans harder into pre-payment scrutiny in 2026, Florida toxicology labs that treat this modifier as a blanket workaround are setting themselves up for denials, recoupments, or worse.
The fix isn’t complicated either. Strengthen your documentation, audit your own frequency data before a payer does, and make sure your coding team and your ordering physicians are speaking the same language. Get that right, and Modifier 91 stops being a liability and goes back to being what it was always meant to be: a straightforward way to bill for legitimate, medically necessary repeat testing.